Literature DB >> 11928810

Plasmin produces an E-cadherin fragment that stimulates cancer cell invasion.

Filip Ryniers1, Christophe Stove, Marc Goethals, Liesbeth Brackenier, Veerle Noë, Marc Bracke, Joël Vandekerckhove, Marc Mareel, Erik Bruyneel.   

Abstract

Matrix metalloproteases from the cell surface cleave an 80 kDa E-cadherin fragment (sE-CAD) that induces invasion of cancer cells into collagen type I and inhibits cellular aggregation. Conditioned media from MDCKts.srcCl2 cells at 40 degrees C and 35 degrees C, PCm.src5 and COLO-16 cells at 37 degrees C contained spontaneously released sE-CAD; these 48 h old conditioned media were capable of inhibiting E-cadherin functions in a paracrine way. Here we show direct cleavage of the extracellular domain of E-cadherin by the serine protease plasmin. sE-CAD released by plasmin inhibits E-cadherin functions as evidenced by induction of invasion into collagen type I and inhibition of cellular aggregation. This functional inhibition by sE-CAD was reversed by aprotinin or by immunoadsorption on protein Sepharose 4 fast flow beads with antibodies against the extracellular part of E-cadherin. Our results demonstrate that plasmin produces extracellular E-cadherin fragments which regulate E-cadherin function in cells containing an intact E-cadherin/catenin complex.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11928810     DOI: 10.1515/BC.2002.016

Source DB:  PubMed          Journal:  Biol Chem        ISSN: 1431-6730            Impact factor:   3.915


  26 in total

1.  DC-CLM, a cadherin-like molecule cloned from human dendritic cells, inhibits growth of breast cancer cells.

Authors:  Yingming Jiang; Tao Wan; Guoyou Chen; Fangming Xiu; Dajing Xia; Weiping Zhang; Xiangyang Zhou; Xuetao Cao
Journal:  J Cancer Res Clin Oncol       Date:  2003-02-12       Impact factor: 4.553

2.  Targeting Cathepsin B for Cancer Therapies.

Authors:  Hang Ruan; Susan Hao; Peter Young; Hongtao Zhang
Journal:  Horiz Cancer Res       Date:  2015 2nd Quarter

3.  ADAM10 mediates E-cadherin shedding and regulates epithelial cell-cell adhesion, migration, and beta-catenin translocation.

Authors:  Thorsten Maretzky; Karina Reiss; Andreas Ludwig; Julian Buchholz; Felix Scholz; Erhardt Proksch; Bart de Strooper; Dieter Hartmann; Paul Saftig
Journal:  Proc Natl Acad Sci U S A       Date:  2005-06-15       Impact factor: 11.205

4.  Fate of E-cadherin in early RPE cultures: transient accumulation of truncated peptides at nonjunctional sites.

Authors:  Janice M Burke; Jeehee Hong
Journal:  Invest Ophthalmol Vis Sci       Date:  2006-08       Impact factor: 4.799

5.  Soluble N-cadherin fragment promotes angiogenesis.

Authors:  L Derycke; L Morbidelli; M Ziche; O De Wever; M Bracke; E Van Aken
Journal:  Clin Exp Metastasis       Date:  2006-09-22       Impact factor: 5.150

Review 6.  E-cadherin's dark side: possible role in tumor progression.

Authors:  Fausto J Rodriguez; Laura J Lewis-Tuffin; Panos Z Anastasiadis
Journal:  Biochim Biophys Acta       Date:  2012-03-13

7.  Human mesenchymal stem cells induce E-cadherin degradation in breast carcinoma spheroids by activating ADAM10.

Authors:  Angela Dittmer; Kristina Hohlfeld; Jana Lützkendorf; Lutz P Müller; Jürgen Dittmer
Journal:  Cell Mol Life Sci       Date:  2009-07-15       Impact factor: 9.261

Review 8.  Soluble cadherins as cancer biomarkers.

Authors:  Olivier De Wever; Lara Derycke; An Hendrix; Gert De Meerleer; François Godeau; Herman Depypere; Marc Bracke
Journal:  Clin Exp Metastasis       Date:  2007-10-19       Impact factor: 5.150

9.  MMP-7 mediates cleavage of N-cadherin and promotes smooth muscle cell apoptosis.

Authors:  Helen Williams; Jason L Johnson; Christopher L Jackson; Stephen J White; Sarah J George
Journal:  Cardiovasc Res       Date:  2010-02-05       Impact factor: 10.787

10.  Cleavage of E-Cadherin by Matrix Metalloproteinase-7 Promotes Cellular Proliferation in Nontransformed Cell Lines via Activation of RhoA.

Authors:  Conor C Lynch; Tracy Vargo-Gogola; Lynn M Matrisian; Barbara Fingleton
Journal:  J Oncol       Date:  2010-06-10       Impact factor: 4.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.